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In the November issue of Environmental
Health Perspectives, Apelberg et al. (2007)
reported an inverse relationship between
umbilical cord blood concentrations of
perfluorooctanoate (PFOA) and perfluoro-
octane sulfonate (PFOS) and ponderal
index and head circumference in children
delivered vaginally in Baltimore, Maryland.
In the same issue, Fei et al. (2007) reported
an inverse relationship between first
trimester maternal blood PFOA (but not
PFOS) concentration and birth weight in
Danish infants born to normal-weight
women. Although these studies do not nec-
essarily support one another (Fei et al. also
collected cord blood but did not report
these results), they raise the important ques-
tion of whether low-level exposure to
perfluoroalkane acids might affect fetal
growth. In both articles, the authors called
attention to the inconsistency between these
findings and those in experimental animal
studies, in which fetal growth effects occur
only at blood concentrations several orders
of magnitude higher than were measured in
human umbilical cord or maternal blood.
The question was reasonably posed by both
groups whether a confounder could be
responsible for the observed associations.
The Baltimore group (Apelberg et al. 2007)
identified two candidate confounders that
may explain their findings: diet and plasma
volume. 
Perfluoroalkanesulfonamides, which may
be metabolized to PFOS, have been used in
grease- and water-repellant packaging for
foods, particularly pizza, french fries, and
other fried foods. The Canadian Total Diet
Study (Tittlemier et al. 2006) detected
perfluoroalkanesulfonamides in all foods
tested, but the highest concentrations were
found in pizza, microwave popcorn, egg
breakfast sandwiches, french fries, chicken
nuggets, and fish burgers. Fluorotelomer
alcohols, which can be converted to the cor-
responding alkane acids, have been used in
coatings for paper, including microwave
popcorn bags. 8-2 Fluorotelomer alcohol can
be converted atmospherically and metaboli-
cally to PFOA, and gavage treatment of
pregnant mice with 8-2 fluorotelomer alco-
hol results in the appearance of PFOA in
fetuses (Henderson and Smith 2007). Both
8-2 fluorotelomer alcohol and PFOA have
been found in popcorn bags and in the vapor
produced after cooking microwave popcorn
(Begley et al. 2005; Sinclair et al. 2007).
The pregnancies studied by Fei et al.
(2007) occurred in 1996–2002, a period
during which perfluorinated compounds
were commonly used in fast-food packaging.
The use of perfluorinated compounds in
food packaging decreased some years before
2004–2005, the study period of Apelberg
et al. (2007); however, PFOS and PFOA
have long half-lives and may still have been
present as markers of a high intake of fast-
food. A high intake of fast food may in turn
be a marker of poor nutrition. The Danish
National Birth Cohort (Fei et al. 2007)
included a food frequency questionnaire. It
would be interesting to know if a relation-
ship between nutrition and maternal blood
perfluoroalkane acid concentration was
detected.
PFOA and PFOS repel fat and are dis-
tributed in body water, particularly plasma.
Women with a reduced plasma or body water
volumes would distribute the same body bur-
den of perfluoroalkane acids in a smaller
space, producing higher perfluoroalkane acid
concentrations. Fat-free body mass and total
body water volumes are important predictors
of birth weight (Butte et al. 2003; Lederman
et al. 1999; Mardones-Santander et al. 1998;
Sanin Aguirre et al. 2004), giving rise to the
possibility that higher maternal blood (and
therefore fetal blood) concentrations of
PFOS and PFOA are markers of reduced
plasma or total body water volumes, pro-
ducing an apparent inverse association
between the perfluoroalkane acid concentra-
tions and fetal growth.
A reasonable next step in addressing the
question of whether perfluoroalkane acids (at
current human blood concentrations) play a
role in fetal growth will be studies in which
maternal nutrition and body composition, as
opposed to body weight, are considered as
possible confounders.
A.R.S. has been a consultant for 3M and has
testified in litigation involving PFOA and
PFOS.
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Perfluoroalkane Acids:
Apelberg et al. Respond
doi:10.1289/ehp.11036R
We thank Scialli for his interest in our study
(Apelberg et al. 2007). As he notes, we recog-
nize that several factors could be responsible
for the relationships observed between cord
serum concentrations of perfluorooctane 
sulfonate/perfluorooctanoate (PFOS/PFOA)
and birth weight, head circumference, and
ponderal index in our study. Although diet
may be a source of exposure (including con-
sumption of polyfluoroalkyl compounds
used in fast-food packaging), we are not
aware of any evidence that such diets are
associated with smaller size at birth. In fact,
they may be related to obesity, which is asso-
ciated with larger birth size (Surkan et al.
2004). Despite existing knowledge gaps on
exposure pathways and the role of dietary
intake, we do know that in our study, adjust-
ing for body mass index of the mother had
little impact on the associations observed. 
Scialli posits that there may be a role of
reduced plasma or body water volume on the
associations observed. As we described in our
article (Apelberg et al. 2007), both pre-
eclampsia and pregnancy-induced hyper-
tension (PIH) are associated with poor
maternal plasma volume expansion (Salas
et al. 2006), as is placental weight (Salas et al.
1993). However, cord concentrations of
PFOS and PFOA were not elevated among
mothers with preeclampsia or PIH, and
adjustment for these conditions did not
appreciably alter the observed associations.
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which may be associated with plasma volume
of the infant, did not alter these associations.
Despite theoretical considerations, we have
not found support for this hypothesis.
Further research is needed to better under-
stand the pathways of human exposure and
the role that pharmacokinetics of these com-
pounds in the human body may play in the
observed associations.
The authors declare they have no competing
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Carcinogenicity of Aspartame
in Rats Not Proven 
doi:10.1289/ehp.10881
In their article on lifetime exposure to
aspartame in rats, Soffritti et al. (2007) pur-
ported that their study demonstrated
increased carcinogenic effects in female rats
as a result of exposure beginning during
prenatal life. 
We believe that this article (Soffritti
et al. 2007) has methodologic and concep-
tual weaknesses that require exposition.
First, although the study was a toxicology
study, the most important element—the
reported doses—are not correct. The doses
are “estimates” based on assuming constant
food consumption of 20 g/day and constant
body weights of 400 g for each rat from
in utero (fetal day 12) to death. These
assumptions are unrealistic and inaccurate.
The doses during the early growth phase of
rats would be much higher because, as is
well known, rats consume more food per
gram of body weight during the rapid
growth phase. Food consumption and body
weight were reportedly measured through-
out the experiment; however, Soffritti et al.
(2007) presented only data beginning
16 weeks postpartum, when rats reached
adult body weight. Therefore the authors’
conclusions are built on the exposure period
for which they provide no data.
Second, for a study allegedly designed to
assess prenatal exposure, Soffritti et al. (2007)
did not address important details, such as
a) pregnancy history and ages of breeders;
b) number of pregnant dams per dose group;
c) growth and food consumption of mothers
during pregnancy and lactation; d) pregnancy
outcomes; e) disposition of pups from all
mothers and each litter; f) the origin of the
70 pups; and g) body weight of pups at birth
and during lactation. These details are typi-
cally required to allow other scientists to
assess the appropriateness of the study design
and to repeat the study, if desired. 
The findings are of questionable
biological significance for a number of rea-
sons. The lymphoma/leukemia incidences
in the high-dose group, which were the
only significant differences from control,
were within or near the reported historical
control ranges. Similarly, the mammary
gland carcinoma incidence in high-dose
females (again, the only significant differ-
ence from control) was similar to historical
controls. In their article, Soffritti et al.
(2007) stated that their study disproved the
conclusions of the European Food Safety
Authority (EFSA 2006) that the incidences
of lymphomas/leukemias observed in the
first report (Soffritti et al. 2006) were
“unrelated to aspartame given the high
background incidence of chronic inflamma-
tory changes in the lungs …” (EFSA 2006).
The U.S. Food and Drug Administration
(FDA 2007) agreed with the EFSA assess-
ment. It is not clear to us how this study
disproved the EFSA’s conclusions. Soffritti
et al. (2007) indicated that the lung was
often the site of lymphoma again in this
study, which is not surprising because they
used the same infected colony. Studies in
the 1960s demonstrated that the progres-
sion of chronic pneumonia in rats resulted
in lymphoid neoplasmas, and elimination
of chronic respiratory disease in rat colonies
reduced the incidence of pulmonary 
lymphoid neoplasias to near zero (Cotchin
and Roe 1967). Rats with pulmonary infec-
tions developed lesions in multiple sites ear-
lier than rats free from pulmonary disease
(Cotchin and Roe 1967). The establish-
ment of pathogen-free animal suppliers for
toxicity research was impelled for this rea-
son. Therefore, we believe it is highly likely
that the present findings are due to infec-
tion and not aspartame consumption.
Data do not support the conclusions of
Soffritti et al. (2007) that aspartame has
carcinogenic potential at doses near the
human level of exposure. The authors
observed no significant effects at the low-
diet level, and the actual dose is unknown.
Also, no data were provided on in utero
exposure. Aspartame is completely digested
in the gastrointestinal tract into two amino
acids (phenylalanine and aspartic acid) and
methanol, which is subsequently metabo-
lized to carbon dioxide and water. In
human clinical studies (reviewed by Stegink
and Filer 1996), oral doses equal to or
exceeding the amount that would represent
the 99th percentile of aspartame intake did
not increase plasma aspartate or phenyl-
alanine levels in adults or children, or in
breast milk from lactating women beyond
normal postprandial concentrations. Ratios
of fetal/maternal plasma amino acids and
transport across the placental membrane
were unchanged in pregnant rabbits that
received 1,600 mg aspartame/kg/day
(Ranney et al. 1975). Thus, a biologically
plausible explanation is lacking for Soffritti
et al.’s (2007) contention that prenatal
exposure to aspartame increases cancer risk.
In summary, considering that there are
no significant differences in cancer rates
between high-dose groups and historical
controls, plus the many deficiencies in the
experimental design and data, Soffritti et al.
(2007) failed to provide convincing evidence
of aspartame carcinogenicity. Given the
effort expended by many government review
agencies to document shortcomings of the
first article by this group (Soffritti et al.
2006), it is disappointing that the editor and
reviewers of this paper (Soffritti et al. 2007)
did not require the authors to address those
problems that appear again in this study.
Diligence is especially necessary on topics of
great public interest and relevance because
the public is relying upon the scientific com-
munity to assure that only high quality, well-
documented, and controlled studies appear
in peer-reviewed journals. 
The authors received payment from the Burdock
Group during the preparation of an expert review
of the safety of aspartame. The Burdock Group
managed the independent review, which was
financially supported by Ajinomoto Company Inc.,
a producer of aspartame.
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Carcinogenicity of Aspartame:
Soffritti Responds
doi:10.1289/ehp.10881R
Magnuson and Williams’s letter is substan-
tially a repetition of the arguments set forth
in a recent article (Magnuson et al. 2007),
which was a “safety evaluation” sponsored
entirely by Ajinomoto, the manufacturer of
aspartame. Their article (Magnuson et al.
2007) and this letter contain numerous erro-
neous statements about the long-term car-
cinogenesis studies on aspartame conducted
by the European Ramazzini Foundation
(ERF).
First, Magnuson and Williams imply
that our findings (Soffritti et al. 2007)
should be discounted because the incidence
of lymphomas/leukemias in the high-dose
group “were within or near the reported his-
torical control ranges.” As reported in our
study (Soffritti et al. 2007), the incidence of
lymphomas/leukemias observed in both
sexes treated with 2,000 ppm aspartame is
nearly double the concurrent control
(Soffritti et al. 2007). The suggestion that
concurrent control data should be ignored is
contrary to the widely accepted standard of
good laboratory science. 
Second, Magnuson and Williams
attribute our findings (Soffritti et al. 2007)
to some kind of bias (i.e., infection) that
would affect only treated animals but not the
controls. We have responded in detail to this
hypothesis in our article (Soffritti et al. 2007)
and in an earlier letter (Soffritti 2006). To
support their assertion, Magnuson and
Williams mislead readers by stating that “the
lung was often the site of lymphoma again in
this [second] study.” However, we actually
reported that 
we observed the diffusion of neoplastic tissue not
only in the lung but also concurrently in various
organs (liver, spleen, mediastinal and other lymph
nodes). (Soffritti et al. 2007)
Infection as a mode of action for induc-
tion of rat lymphoma has been recently
examined by a group of scientists at the
National Center for Environmental
Assessment of the U.S. Environmental
Protection Agency; Caldwell et al. (2008)
found that 
a careful examination of available information
does not support the hypothesis that the observed
lymphomas/leukemias in the ERF bioassays are a
general effect from infection. The reports of
chemically-induced lymphomas/leukemias by the
ERF seem to be chemical specific.
Third, the idea that we must provide a
“biologically plausible explanation” for
human or rodent carcinogens is a time-
honored approach to postpone or prevent
the application of regulatory measures to
minimize carcinogenic risks. The reality is
that this explanation is quite often unknown,
as is, in general, the mode of action behind
the carcinogenic process. 
I regard the other questions raised by
Magnuson and Williams as trivial. For
example, whatever the doses at various ages
and weights, the finding of any effect should
be a cause for concern. Likewise, the authors’
observation that some methodologic details
were omitted from the publication certainly
does not change the oncologic results of this
research. 
Magnuson and Williams express disap-
pointment that Environmental Health
Perspectives would publish original scientific
research by the ERF after regulatory agen-
cies went through so much trouble to review
our first aspartame study (Soffritti 2006)
only to disagree with our conclusions. It is
the obligation of the agencies responsible
for food safety to review any new scientific
data available and to make their opinion
available to the public. The Food and Drug
Administration (FDA) did not make public
the contents of their review, but rather they
issued a short press release a full year after
the European Food Safety Authority (EFSA)
concluded its evaluation, and coincidently,
just days before I presented new aspartame
data in a lecture at the Mount Sinai School
of Medicine in New York (FDA 2007). 
I find it unfortunate that some scientists
have such a low tolerance for original, inde-
pendent scientific research; however, I wel-
come continued discussion and more
importantly, additional long-term experi-
mental studies on aspartame and other artifi-
cial sweeteners. We at the ERF stand behind
our results, and we remain convinced that a
review of the current regulations governing
the use of aspartame is necessary to better
protect public health. 
The author declares he has no competing
financial interests.
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Food Additives and
Hyperactivity
doi:10.1289/ehp.11182
In the December 2007 Forum article on the
links between food additives and hyper-
activity, Barrett (2007) offered a somewhat
distorted perspective on the public health
implications of these additives. Barrett
described a clinical trial testing the proposi-
tion that consumption of a blend of artifi-
cial food flavors and sodium benzoate
induces changes in children’s behavior
(McCann et al. 2007). The results of that
study support such a claim.
Barrett (2007) fumbled the significance
of the trial (McCann et al. 2007) for envi-
ronmental health. The Forum article
emphasized how food additives might con-
tribute to the clinical diagnosis of attention
deficit/hyperactivity disorder rather than on
the more significant finding that food
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els prevailing in the diet, induce adverse
behavioral responses. This is hardly a novel
finding. In 1980, such effects were docu-
mented in two different groups of subjects
with two different experimental designs
(Swanson and Kinsbourne 1980; Weiss
et al. 1980). Many later publications have
confirmed their results. I briefly reviewed
the data in Environmental Health Perspectives
(Weiss 2000).
According to Barrett (2007), a Food and
Drug Administration (FDA) official, Mike
Herndon, maintains that the agency sees
“… no reason at this time to change our
conclusions that the ingredients that were
tested in this study that currently are permit-
ted for food use in the United States are safe
for the general population.” This is a rather
baffling statement. In fact, our study (Weiss
et al. 1980) was funded by the FDA, and its
results, along with a number of others from
that period, definitively demonstrated
adverse behavioral effects of synthetic food
colors (Weiss 1982). During the intervening
years, with a plethora of confirmations, the
FDA has remained blindly obstinate. It con-
tinues to shield food additives from testing
for neurotoxicity and apparently believes that
adverse behavioral responses are not an
expression of toxicity.
Herndon and the FDA should seriously
consider what the late Philip Handler said
about balancing risks and benefits:
A sensible guide would surely be to reduce expo-
sure to hazard whenever possible, to accept sub-
stantial hazard only for great benefit, minor hazard
for modest benefit, and no hazard at all when the
benefit seems relatively trivial. (Handler 1979)
The FDA has never clarified the health
benefits of artificial food colors.
The author declares he has no competing
financial interests.
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Editor’s note—Weiss correctly points out
that several investigators, including himself,
have reported links between food additives and
hyperactivity in children. He is also correct in
stating that food additives appear to exacerbate
existing hyperactive behavior in children,
rather than contribute to the clinical diagnosis
of attention deficit/hyperactivity disorder
(ADHD). The study by McCann et al. [Lancet
370:1560–1567 (2007)] supports that conclu-
sion, as described in Barrett’s December 2007
Forum article [Environ Health Perspect
115:A578 (2007)].
We believe it was important to mention
ADHD because hyperactivity and clinically
defined ADHD are often conflated in the
science news press. The point of referring to
ADHD and therein clarifying the relationship
between ADHD and hyperactivity was to put
the import of the findings by McCann et al.
(2007) into proper perspective.
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ERRATA
Fox et al. [Environ Health Perspect
116:618–625 (2008)] inadvertently used
the wrong calibration unit in the text and
Figure 3 of their article. Candela-seconds
per square meter (cd-sec/m2) should have
been Trolond-seconds (td-sec) throughout.
The authors regret the error.
In the statistical analysis section of
“Hypertension and Exposure to Noise
Near Airports: the HYENA Study”
[Environ Health Perspect 116:329–333
(2008)], Jarup et al. erroneously named
Biostat International (Tampa, FL) as the
manufacturer of the meta-analysis
software used in the study. The soft-
ware is actually produced by Biostat
(Englewood, NJ). 
The authors regret the error.